Drug Trial Radar · NCT01230814
Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
Last checked: Nov 19, 2026Latest source record: Oct 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
234
Actual
Start
Apr 2011
Primary completion
Aug 2013
Study completion Aug 2013
Sponsor
- Sponsor type
- NIH
- First posted
- Oct 29, 2010
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study is about vaginal infections such as bacterial vaginosis, yeast infections, and trichomoniasis. Usually, these infections can be treated with medication, but sometimes they come back after treatment. Researchers want to know if using vaginal suppositories can decrease the risk of vaginal infections. Participants will include 234 women who are sexually active (greater than or equal to 4 episodes of sex with men during the past month), HIV-negative, 18 to 45 years old, with bacterial infection \[vaginosis and/or vulvovaginal candidiasis (VVC) and/or Trichomonas vaginalis\] detected by laboratory testing at a screening visit. Women will receive vaginal suppositories containing drug or inactive ingredients (placebo). Participation in the study will be about 12 months. Study procedures include: urine and blood tests, physical exams, and questionnaires.
Conditions
- Bacterial Vaginosis
- Candidiasis
- Trichomoniasis
Interventions
Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)Drug
Neo-Penotran® Forte (active ingredient Metronidazole \& Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
PlaceboDrug
Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Vulvovaginal Candidiasis (VVC).Time frame: Months 2, 4, 6, 8, 10, and 12.
- Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights Each Month for Preventing Bacterial Vaginosis (BV).Time frame: Months 2, 4, 6, 8, 10, and 12.
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham Medical Center
Birmingham, Alabama
Women's Health Project - Ganjoni Municipal Clinic
Mombasa, Coast, Kenya
University of Nairobi - Center for STD/HIV Research & Training
Nairobi, Nairobi County, Kenya
University of Nairobi - Kenya AIDS Vaccine Initiative
Nairobi, Nairobi County, Kenya
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.